What is Brainomix?
Brainomix, established in 2010 as a spin-off from the University of Oxford, specializes in developing artificial intelligence-driven software designed to enhance the efficacy of life-saving medical treatments. Its flagship e-Stroke platform offers clinicians a comprehensive solution for stroke imaging analysis, enabling quicker and more informed treatment decisions for patients experiencing suspected strokes. The company's focus on AI in healthcare positions it at the forefront of medical technology innovation.
How much funding has Brainomix raised?
Brainomix has raised a total of $52.5M across 5 funding rounds:
Angel/Seed
$1.9M
Series A
$1.6M
Other Financing Round
$9.8M
Series B
$21.2M
Series C
$18M
Angel/Seed (2014): $1.9M with participation from Parkwalk Advisors Limited
Series A (2014): $1.6M led by University of Oxford Isis Fund and Chimera Partners
Other Financing Round (2018): $9.8M supported by Boehringer Ingelheim, Parkwalk Advisors, Chimera Partners, and Oxford University Innovation Fund
Series B (2021): $21.2M featuring Oxford University Innovation Fund, Boehringer Ingelheim Venture Fund, Parkwalk Advisors, and Tencent
Series C (2025): $18M backed by Hostplus, Parkwalk Advisors, and Boehringer Ingelheim Venture Fund
Key Investors in Brainomix
Boehringer Ingelheim
Boehringer Ingelheim is a research-driven pharmaceutical company with a broad focus on human pharma, animal health, and biopharmaceutical contract manufacturing, investing in companies that advance medical treatments.
Parkwalk Advisors
Parkwalk Advisors is a prominent investor in university spinouts, specializing in deeptech innovations and providing crucial funding and expertise to emerging technology companies.
Boehringer Ingelheim Venture Fund
The Boehringer Ingelheim Venture Fund invests in pioneering science and therapeutics, aiming to redefine care standards and develop novel medicines across various modalities.
What's next for Brainomix?
The recent major strategic investment into Brainomix signals a strong validation of its technology and market potential. This capital infusion is expected to fuel further development of its AI-powered diagnostic tools, expand its market reach, and potentially drive new research initiatives. As Brainomix continues to scale, its focus on improving patient outcomes through advanced imaging analysis will likely remain central to its growth strategy, solidifying its position in the competitive health-tech landscape.
See full Brainomix company page
